

Consultation on draft guideline – deadline for comments [5pm] on [07/06/2022]

email: tobaccoadditional@nice.org.uk

Checklist for submitting comments

- Use this comments form and submit it as a Word document (not a PDF).
- Complete the disclosure about links with, or funding from, the tobacco industry.
- Include document name, page number and line number of the text each comment is about.
- Combine all comments from your organisation into 1 response form. We cannot accept more than 1 response from each organisation.
- **Do not** paste other tables into this table type directly into the table.
- Ensure each comment stands alone; **do not** cross-refer within one comment to another comment.
- Clearly mark any confidential information or other material that you do not wish to be made public. Also, ensure you state
 in your email to NICE that your submission includes confidential comments.
- **Do not name or identify any person or include medical information about yourself or another person** from which you or the person could be identified as all such data will be deleted or redacted.
- Spell out any abbreviations you use.
- For copyright reasons, **do not include attachments** such as research articles, letters, or leaflets. We return comments forms that have attachments without reading them. You may resubmit the form without attachments, but it must be received by the deadline.
- We do not accept comments submitted after the deadline stated for close of consultation.

You can see any guidance that we have produced on topics related to this guideline by checking <u>NICE Pathways</u>.

Note: We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.



Consultation on draft guideline – deadline for comments [5pm] on [07/06/2022] email: tobaccoadditional@nice.org.uk

	Please read the checklist above before submitting comments. We cannot accept forms that are not filled in correctly.				
	We would like to hear your views on the draft recommendations presented in the guideline, and any comments you may have on the rationale and impact sections in the guideline and the evidence presented in the evidence reviews documents. We would also welcome views on the Equality Impact Assessment.				
	In addition to your comments below on our guideline documents, we would like to hear your views on these questions. Pleatinclude your answers to these questions with your comments in the table below.				
	 Which areas will have the biggest impact on practice and be challenging to implement? Please say for whom and why. Would implementation of any of the draft recommendations have significant cost implications? What would help users overcome any challenges? (For example, existing practical resources or national initiatives.) 				
	See <u>Developing NICE guidance: how to get involved</u> for suggestions of general points to think about when				
	commenting.				
Organisation name (if you are responding as an individual rather than a registered stakeholder please specify).	Company Chemists' Association				
Disclosure (please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry).	None				
Name of person completing form	Destina Thompson				



Consultation on draft guideline – deadline for comments [5pm] on [07/06/2022]

email: tobaccoadditional@nice.org.uk

Comment number	Document [e.g. guideline, evidence review A, B, C etc., methods, EIA]	Page number 'General' for comments on whole document	Line number 'General' for comments on whole document	Insert each comment in a new row. Do not paste other tables into this table, because your comments could get lost – type directly into this table. Include section or recommendation number in this column.
1	Guideline	7	1.12.5	The guidelines recommend that behaviour support is offered to people who smoke regardless of which option they choose. Evidence shows smoking cessation services delivered by community pharmacy are effective and cost-effective, particularly for vulnerable or deprived communities. A systematic review and meta-analysis by Brown et al. (2016) showed that delivering smoking cessation services through community pharmacy is both effective and cost-effective when compared with usual care. The guidelines should reflect that smoking cessation support already exists in community settings and ensure that pharmacy-led interventions are promoted as an option for patients. As of March 2022, the Smoking Cessation Service has been introduced as an advanced service in the CPCF. This service will enable NHS trusts to refer patients discharged from hospital to a community pharmacy of their choice to continue their smoking cessation care pathway, including providing medication and behavioural support as required, in line with the NHS Long Term Plan care model for tobacco addiction. Recently available data suggests that more than 2,000 pharmacies have signed up to deliver the service. There should be greater promotion of the service within secondary care settings to ensure a continuity of support for patients in hospital and upon discharge into the community.
2	Guideline	7	1.12.3	The guidelines suggest that NRT should be considered for smokers under the age of 16. Under a framework of Gillick competence, patients who smoke and are under 16 should be reassured that clinicians will not inform their parents or guardians. Adolescents in particular may need this reassurance so that they are not deterred from seeking and/or adhering to smoking cessation support
3				
4		_		
5				
6				
7				
8				
9				



Consultation on draft guideline – deadline for comments [5pm] on [07/06/2022] email: tobaccoadditional@nice.org.uk

10						
Insert extra rows as needed						

Data protection

The information you submit on this form will be retained and used by NICE and its advisers for the purpose of developing its guidance and may be passed to other approved third parties. Please do not name or identify any individual patient or refer to their medical condition in your comments as all such data will be deleted or redacted. The information may appear on the NICE website in due course in which case all personal data will be removed in accordance with NICE policies.

By submitting your data via this form you are confirming that you have read and understood this statement.

For more information about how we process your data, please see our privacy notice.